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Abstract
Glyoxalase I (GLO1), a methylglyoxal detoxification enzyme, is implicated in the progression of human malignancies. The
role of GLO1 in gastric cancer development or progression is currently unclear. The expression of GLO1 was determined in
primary gastric cancer specimens using quantitative polymerase chain reaction, immunohistochemistry (IHC), and western
blotting analyses. GLO1 expression was higher in gastric cancer tissues, compared with that in adjacent noncancerous
tissues. Elevated expression of GLO1 was significantly associated with gastric wall invasion, lymph node metastasis, and
pathological stage, suggesting a novel role of GLO1 in gastric cancer development and progression. The 5-year survival rate
of the lower GLO1 expression groups was significantly greater than that of the higher expression groups (log rank
P=0.0373) in IHC experiments. Over-expression of GLO1 in gastric cancer cell lines increases cell proliferation, migration and
invasiveness. Conversely, down-regulation of GLO1 with shRNA led to a marked reduction in the migration and invasion
abilities. Our data strongly suggest that high expression of GLO1 in gastric cancer enhances the metastasis ability of tumor
cells in vitro and in vivo, and support its efficacy as a potential marker for the detection and prognosis of gastric cancer.
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Introduction
Gastric cancer is the fourth most common form of cancer and
the second highest cause of cancer-related mortality worldwide
[1]. The malignancy is the sixth leading cause of cancer-related
deaths in Taiwan [2]. Proper screening can facilitate the detection
of gastric cancer before symptom development at a curable stage
[3]. Determination of the expression profiles of key molecules in
the several pathways involved in gastric cancer progression may
aid in diagnosis, prognosis and prediction of tumor progression.
Tumor invasion and metastasis are vital steps in determining the
aggressive phenotype of human cancers, and constitute the
principal causes of cancer-related death [4]. High expression of
migration-related factors, such as cyclooxygenase 2 (COX-2) [5],
Vascular endothelial growth factor (VEGF) [6], CXC chemokine
ligand (CXCL)-8 [7], chemokine (C-X-C motif) receptor (CXCR)-
2, and CXCL-1 [8], are associated with gastric cancer progression.
Several potential oncogenic pathways (proliferation/stem cell, NF-
kB, and Wnt/b-catenin) are deregulated in the majority of gastric
cancers [9]. Thus, further elucidation of the exact molecular
events leading to gastric cancer progression and identification of
valuable diagnostic or prognostic markers and novel therapeutic
strategies would be of significant clinical value.
Glyoxalase I (also termed GLO1) is an essential component in
pathways leading to the detoxification of Methylglyoxal (MG), one
of the side products of glycolysis [10,11,12]. GLO1 expression is
increased in several human cancers of the colon, breast, prostate,
and melanoma [13,14,15,16,17]. Recent studies have reported
that over-expression of GLO1 is associated with cancer progres-
sion and drug resistance [17]. From our previous data, GLO1
upregulation was observed in gastric cancer specimens using
cDNA microarray [18]. However, the specific role of GLO1
during gastric tumorigenesis and its clinical significance remain to
be established.
Our experiments clearly show that GLO1 is frequently over-
expressed in gastric cancer and associated with cancer metastasis.
Notably, expression of GLO1 is significantly higher in advanced
stages of gastric cancer. Furthermore, alterations the expression of
GLO1 in gastric cancer cell lines affects cell migration and
invasion abilities.
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Ethics Statement
The study protocol was approved by the Medical Ethics and
Human Clinical Trial Committee of the Chang Gung Memorial
Hospital (IRB NO. 95-0472B). Written informed consent was
obtained from all patients.
Subjects
The 114 patients (64 males and 50 females; median age, 66
years; range 28–86 years) diagnosed with gastric cancer at the
Chang Gung Memorial Hospital from 2000 to 2005 were enrolled
in this study. All patients received surgery for primary gastric
cancer without prior chemotherapy or radiotherapy. Each patient
was subjected to gastric resection (35 patients underwent total
gastrectomy and 79 partial gastrectomy).
Clinicopathological studies
Resected specimens were examined pathologically using the
criteria of the Japanese General Rules for Gastric Cancer Study
[19] and the American Joint Committee on Cancer (AJCC) (pTNM)
classification system [20]. Clinicopathological parameters included
patient age and gender, tumor location and size, gross (Borrmann’s)
tumor type, wall invasion, resection margin, histological type, lymph
node metastasis, vascular invasion, lymphatic invasion, and perineu-
ral invasion. After discharge, all patients had periodic follow-up visits
at the outpatient department of Chang Gung Memorial Hospital
until death or the beginning of preparation of this article.
Real-time quantitative reverse transcription polymerase
chain reaction (qRT–PCR)
qRT–PCR was performed as described in a previous report [21].
The following primers were used: human GLO1 qRT–PCR (forward
primer, 59–TGAGGATAAAAATGACATCCCTA- AAGA–39,
and reverse primer, 59–TGTGTCAGCTCAAGTGTAGCTTTC–
39), human 18S rRNA qRT–PCR (forward primer, 59–
CGAGCCGCCTGGATACC–39, and reverse primer, 59–
CCTCAGTT CCGAAAACCAACAA–39).
Production of anti-GLO1 antibody
The cDNA encoding full-length GLO1 was cloned into pGEX-4T1.
Lysates from E. coli BL21 strain were purified with glutathione-agarose
beads (Sigma-Aldrich, St. Louis, MO). Soluble proteins were purified
using chromatography with glutathione-agarose beads, according to
the manufacturer’s instructions, emulsified with adjuvant, and used to
immunize rabbits. Polyclonal antibodies were produced and affinity-
purified, as described previously [22]. The specificity of in-house
GLO1 was validated using western blot analysis (Figure S1).
Immunoblot analysis
Whole cell lysates, nuclear extracts, and conditional media were
prepared from human tissue or stable GLO1 knockdown cell lines.
Western blotting was performed using monoclonal antibodies against
human HIF-1a (Abcam, San Francisco, CA), p65 (Epitomic,
Burlingame, CA), or p50 (Millipore, Billerica, MA) or polyclonal
antibodies against human GLO1 (in-house, dilution, 1:500), CXCL1
(PeproTech. Inc., Rocky Hill, NJ), CXCL8 (R&D Systems Inc.,
Minneapolis, MN), VEGF (Santa Cruz Biotechnology, Santa Cruz,
CA).
Immunohistochemistry (IHC)
Formalin-fixed and paraffin-embedded tissues were examined
with IHC using the polyclonal antibody against human GLO1
produced in-house (dilution, 1:3000) and the avidin–biotin
complex (ABC) method, as described previously [23,24]. Com-
parisons were performed between the intensity of staining of
carcinoma cells and benign superficial epithelium, which were
placed on the same slide. For semi-quantitative analysis of GLO-1
immunoreactivity, a Histoscore (H)-scoring system was used [25].
Briefly, the negative group consisted of cancer cells with no
detectable (2) or only trace staining for GLO-1 (+1). The positive
group consisted of cancer cells with moderate (+2) or high levels
(+3) of GLO-1 immunoreactivity. The H-scoring was calculated
and averaged by two independent pathologists, blinded to the
initial score for each patient. The results were scored by
multiplying the percentage of positive cells (P) by the intensity
(I), according to the formula: H=P6I. For example, a section in
which 10% of the tissue had a staining score of +1, 60% a score of
+2, and 30% a score of +3, H=(1061)+(6062)+(3063)=220.
Establishment of GLO1 over-expression in SC-M1 cell line
The SC-M1 cell line expressing lower level of GLO1 was used.
The transfection of GLO1 cDNA was performed with Lipofecta-
mine Reagent (Life Technologies, Grand Island, NY). After
incubation for 24 h, the cells were transferred to medium
containing G418 for selection, and were then used in proliferation,
migration, and invasion assays.
Establishment of GLO1 knockdown in TSGH and AGS cell
lines
Two human gastric cancer cell lines, AGS, and TSGH, were
employed. The short hairpin RNA (shRNA) sequences targeting
GLO1 (TRCN0000118630 and TRCN0000118631) were pur-
chased from the National RNA Interference Core Facility
(Institute of Molecular Biology, Academia Sinica, Taiwan). The
specific repression of GLO1 was confirmed using western blot
analysis.
Cell proliferation assay
Cells (1610
4) were grown on a 6 cm plate at 37uC under 5%
CO2. At each time point, the growth rate of the cells was
determined by cell counting. The results are given as the fold
change relative to each control value.
In vitro assay of migration and invasive activity
The effect of GLO1 depletion or over-expression on the
migration and invasive activity of gastric cancer cell lines was
assessed using a rapid in vitro assay (Transwell technique), as
described previously [26].
RNA preparation and microarray analysis
The GLO1-silenced clone TSGH (KG2) and control cell clone
(C1) were rinsed briefly with ice-cold PBS and lysed in TRIzol
reagent (Invitrogen) for RNA extraction. Gene expression profiles
between KG2 and C1 cells were analyzed with the human U133A
GeneChip (Affymetrix, Santa Clara, CA) according to the
manufacturer’s protocol [27].
Statistical analysis
The GLO1 expressions of each subgroup of clinicopatholgoical
parameters in Table 1 are expressed as mean 6 standard
deviation (SD) of the IHC score of the patients in this subgroup.
The Kolmogorov-Smirnov test is a nonparametric test to compare
samples with a reference probability distribution. Where appro-
priate, the Mann-Whitney U or Fisher’s exact test was applied for
comparisons between the two groups, while Kruskal-Wallis or
GLO1 Overexpression in Gastric Cancer
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groups. The relationship between data obtained from the two
different examinations was analyzed with the Spearman’s
correlation test. Patients were monitored until the time of
manuscript preparation or death. Cancer-specific survival out-
come was determined by applying the Kaplan-Meier method for
all patients, except those who died from surgical complications.
The log-rank test was employed to compare the prognostic
significance of individual variables on survival. The Cox
proportional hazards model was employed in multivariate analysis
to identify the independent predictors of survival. P values ,0.05
were considered significant.
Results
GLO1 mRNA and protein levels are upregulated in gastric
cancer patients
Using cDNA microarray, we have identified several upregulated
genes from gastric tissues, compared to adjacent nontumorous
tissues [18]. Among these genes, we focused on GLO1 as a
molecular target for gastric cancer. Expression of GLO1 was
measured in cancer tissues, and compared with that in matched
nontumorous gastric mucosa, using qRT–PCR (n=89) (Table 2)
or IHC (n=114) (Table 1). Data from qRT-PCR experiments
revealed GLO1 overexpression ($1.5-fold) in 51 (57.3%) of gastric
cancer tissues, compared with noncancerous tissues. The mean
GLO1 expression in tumor tissues was 2.87-fold that in
noncancerous tissues. Our results confirmed a significant increase
in GLO1 expression in tumor tissues (P=0.005, one-sample
Kolmogorov-Smirnov test).
Expression of GLO1 protein in paired specimens was further
analyzed using western blotting. Figure 1A presents GLO1
expression in eight representative patients. Equal amounts of total
proteins stained with Coomassie blue after SDS-PAGE were used
as the loading control. All cancer tissues from gastric cancer
samples (G1 to G8) displayed upregulated GLO1 expression,
compared with matched noncancerous adjacent mucosa (Fig. 1A).
Immunostaining demonstrates GLO1 protein over-
expression in gastric cancerous tissues
To further establish whether GLO1 upregulation is correlated
with clinical progression of gastric cancer, IHC was performed on
paraffin-fixed gastric cancer tissues and matched noncancerous
mucosa of 114 patients. Four pairs of representative cases (a/b, c/
d, e/f, and g/h) are shown in Figure 1B. IHC data for
noncancerous mucosa counterparts (a, c, e, and g) and cancer
tissues (b, d, f, and h) were compared in pairs. Dark-brown
immunostaining was mostly prevalent in cancer cells whereas
levels of staining were lower in stromal cells or fibroblasts of gastric
cancer tissues. Strong staining for GLO1 was frequently observed
in advanced gastric tumor cells, in contrast to weak or no staining
Table 1. Clinicopathological Correlations of GLO1 expression
and 5-year Survival Rate in 114 Gastric Cancer Patients.
Parameters No. IHC GLO1
1 P value
2 5-yr S.R.
3 logrank P
4
Age (yrs)
,65 55 129.6657.1 0.096 45.5 0.4133
$65 59 149.3666.8 53.2
Gender
Male 64 147.3659.9 0.178 47.4 0.4958
Female 50 130.2665.7 51.5
Location
Upper third 26 136.9665.1 0.679 53.9 0.4288
Middle third 26 129.6661.9 48.7
Lower third 59 143.7660.6 49.2
Whole 3 176.76107.9 0
Gross type
Localized 43 127.2660.7 0.097 75.8 ,0.0001
Infiltrative 71 147.5663.3 33.1
size
,5 cm 58 130.2655.6 0.158 71.0 ,0.0001
$5 cm 56 149.8668.6 25.1
Histological type
Intestinal 36 141.7659.3 0.555 73.9 0.0002
Diffuse 78 139.0664.7 37.2
Depth of invasion
T1,2 42 113.6658.2 0.001 82.8 ,0.0001
T3,4 72 115.1660.6 28.8
Lymph node
metastasis
No 31 108.1663.0 ,0.001 92.2 ,0.0001
Yes 83 151.7658.8 33.6
Distant metastasis
No 85 134.2658.7 0.277 63.5 ,0.0001
Yes 29 156.2672.2 0.0
Pathological stage
Stages 1,2 39 103.9652.2 ,0.001 89.9 ,0.0001
Stages 3,4 75 158.5659.9 27.0
Liver metastasis
No 112 139.0662.8 0.352 50.2 0.0267
Yes 2 185.0663.6 0.0
Peritoneal seeding
No 93 137.7660.1 0.758 59.0 ,0.0001
Yes 21 149.1674.8 0.0
Vascular invasion
No 89 133.8657.9 0.144 57.6 0.0001
Yes 25 161.2675.4 8.2
Lymphatic invasion
No 47 123.0667.9 0.016 77.2 ,0.0001
Yes 67 151.6656.6 28.7
Perineural invasion
No 71 133.0662.9 0.164 62.0 0.0012
Yes 43 151.2661.7 25.4
GLO1 (IHC score)
Table 1. Cont.
Parameters No. IHC GLO1
1 P value
2 5-yr S.R.
3 logrank P
4
,90 24 55.8620.2 69.6 0.0373
$90 90 162.2649.9 43.3
1IHC scores of GLO1; in mean6standard deviation.
2Mann-Whitney U test (for 2 groups) or Kruskal Wallis test (for .2groups).
35-year survival rate.
4Log rank test.
doi:10.1371/journal.pone.0034352.t001
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was more intense at the advanced gastric cancer stages [stage III in
Fig. 1B (f, h)], compared with stages I [Fig. 1B (b)] and II [Fig. 1B
(d)]. Among the 114 patients analyzed, the mean IHC score in
tumor tissues was 139.8662.8, which was significantly greater
than that (36.7640.4) in the matching adjacent mucosa (n=87)
(P,0.001, Wilcoxon signed-rank test). Furthermore, paired
comparison of immunoreactivity for GLO1 (n=87) revealed that
the IHC scores of cancerous tissues were higher than those of the
nontumorous counterparts in 77 (88.5%) patients, equal in three
patients (3.4%), and lower in seven patients (8.0%).
GLO1 expression and clinical correlations
GLO1 expression in tumor tissue was not significantly
associated with age, tumor location or histological type (Tables 1
and 2). Higher levels of GLO1 were evident in the T3/T4 groups
where the serosal surface of the gastric wall was invaded by cancer,
compared to that in T1/T2 groups where no invasion was evident
(P=0.015 for qRT- PCR and P=0.001 for IHC; Fig. 2A; Tables 1
and 2). Expression of GLO1 was significantly increased, with
metastasis to the lymph nodes (P=0.001 for qRT-PCR and
P,0.001 for IHC; Fig. 2B; Tables 1 and 2). Higher expression was
evident in patients with lymphatic invasion (P=0.001 and
P=0.016 for qRT-PCR and IHC respectively; Tables 1 and 2)
and perineural invasion (P=0.024 for qRT-PCR, Table 2).
Increased GLO1 expression was not associated with vascular
invasion or distant metastasis, including peritoneal seeding or liver
metastasis, in both qRT-PCR and IHC experiments. Expression
of GLO1 was significantly higher in patients with more advanced
pathologic stages (III/IV) of gastric cancer, compared to those in
the earlier pathologic stages (I/II) (P=0.001 and P,0.001 for
qRT-PCR and IHC, respectively) (Fig. 2C; Tables 1 and 2).
Survival outcomes
The mean duration of the follow-up period for 52 survivors was
70.4 months (range, 28–119 months). Four patients died of
postoperative complications and six of other causes. Fifty-two
patients died owing to gastric cancer progression. The overall
cumulative five-year survival rate of the 114 patients was 49.3%
after gastrectomy. To determine the influence of GLO1 expression
on survival outcome, the patient was divided into two groups,
higher and lower expressions, according to the cutoff value which
would demonstrate a significant difference (log rank P,0.05) in
survival rates between 2 groups. The median (=140), upper
quartile (=180 or 75
th percentile), and lower quartile (=90 or 25
th
percentile) of IHC scores of our patient were initially tested to
determine the cutoff values. Among them, only the lower quartile
could show a significant difference in survival outcome. Fig. 2D
illustrates the cumulative survival curves of patients in the lower
and higher expression GLO1 groups, divided according to a cutoff
Table 2. Clinicopathological Correlations of GLO1 expression (Q-RT-PCR) in 89 Gastric Cancer Patients.
Parameters No. GLO1
1
P
value
2 Parameters No. GLO1
1
P
value
2
Age (yrs) Lymph node
metastasis
,65 46 2.663.2 0.386 No 29 1.460.9 0.001
$65 43 3.163.0 Yes 60 3.563.6
Gender Distant metastasis
Male 51 2.863.3 0.816 No 66 2.562.3 0.616
Female 38 2.862.9 Yes 23 3.964.7
Location Pathological stage
Upper third 23 2.762.8 0.656 Stages 1,2 33 1.460.9 0.001
Middle third 19 2.362.7 Stages 3,4 56 3.763.6
Lower third 42 3.263.6 Liver metastasis
Whole 5 2.261.7 No 87 2.963.2 0.923
Gross type Yes 2 2.061.4
Localized 37 1.961.7 0.043 Peritoneal seeding
Infiltrative 52 3.563.7 No 71 2.462.1 0.176
Size Yes 18 4.865.2
,5 cm 48 1.961.7 0.014 Vascular invasion
$5 cm 41 3.964.0 No 70 2.863.2 0.548
Histological type Yes 19 3.063.0
Intestinal 31 2.662.2 0.624 Lymphatic invasion
Diffuse 58 3.063.5 No 38 1.661.3 0.001
Depth of invasion Yes 51 3.863.7
T1,2 35 1.761.3 0.015 Perineural invasion
T3,4 54 3.663.7 No 58 2.262.2 0.024
Yes 31 4.064.1
1Folds: measured by real time Q-RT-PCR in tumor tissues compared to adjacent non-tumor tissues; in mean6standard deviation.
2Mann-Whitney U test (for 2 groups) or Kruskal Wallis test (for .2 groups).
doi:10.1371/journal.pone.0034352.t002
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e34352Figure 1. GLO1 expression is elevated in human gastric carcinoma. Overexpression of GLO1 protein in gastric carcinoma. (A) Western blot
demonstrating the presence of GLO1 protein in cancer tissues. GLO1 proteins were overexpressed in most tumor tissues (T), compared with matched
noncancerous adjacent mucosa (N). All cancer tissues from gastric cancer specimens (G1 to G8) displayed upregulation of GLO1, compared with
matched noncancerous adjacent mucosa. An equivalent amount (30 mg) of protein was loaded for each specimen and subjected to 12% SDS-PAGE,
followed by staining with Coomassie blue as a loading control. Rabbit polyclonal antibody against human GLO1 produced in-house was used. (B)
Panels a, c, e, and g depict noncancerous mucosa, while panels b, d, f, and h depict gastric cancer tissues. Positive staining for GLO1 is indicated as a
dark-brown color. GLO1 expression was observed predominantly in gastric cancer cells and rarely in stromal cells. Scale bar represents 100 mm.
doi:10.1371/journal.pone.0034352.g001
Figure 2. Scatter plots of IHC scores of GLO1 and various clinicopathological features. (A) Scatter plot according to depth of wall invasion
(P=0.001, T1/T2 vs. T3/T4). (B) Scatter plot according to lymph node metastasis (P,0.001, N0 versus N1–3). (C) Scatter plot according to pathological
stage (P,0.001, stages I/II versus stages III/IV). (D) Kaplan-Meir survival curves of two groups of gastric cancer patients defined by a GLO1 expression
level cutoff value of 90, established on the basis of IHC scoring. The 5-year survival rate of the lower expression groups (n=24) was significantly better
than that of the higher expression groups (n=90; 69.6% vs. 43.3%; log rank P=0.0373).
doi:10.1371/journal.pone.0034352.g002
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expression groups was significantly greater than that of the higher
expression groups (69.6% vs. 43.3%; log rank P=0.0373) in IHC
experiments. Univariate analysis disclosed a number of significant
prognostic factors, including status of lymph node metastasis,
distant metastasis, peritoneal seeding, vascular invasion, lymphatic
invasion, depth of invasion, pathological stage, liver metastasis and
perineural invasion, in addition to GLO1 expression. Other
significant parameters were histological type, tumor size, and gross
type (Table 1). Further, in multivariate analysis, the independent
prognostic factors influencing patient survival included lymph
node metastasis (relative risk=5.954, 95% CI=1.183–29.977,
P=0.031) and distant metastasis (relative risk=2.464, 95%
CI=1.030–5.896, P=0.043).
Over-expression of GLO1 in SC-M1 enhances cell
proliferation, migration and invasion activities. To
determine the effects of over-expression of GLO1 in SC-M1 cells,
cell proliferation, migration, and invasion activities were assayed.
After two weeks of transfection, stable expression of GLO1 protein
was established. Figure 3A shows 2.36 fold and 2.29 fold higher
GLO1 expression, respectively. Cell proliferation was determined
by cell counting and indicated as a fold of the control for up to five
days. GLO1-overexpressing cells exhibited significantly (P,0.01)
higher proliferation rates (1.86- or 2.06-fold) than those transfected
with control vector on day 5 (Fig. 3B). Moreover, GLO1-
overexpressing cells displayed significantly (P,0.01) higher
migration rates (5.53- or 4.57-fold) and invasive abilities (3.7- or
3.47-fold) than their control counterparts (Figs. 3C and D). Images
of cell density were shown for two control and two over-expressing
cell lines (left panels in Figs. 3C and D).
Down-expression of GLO1 in TSGH or AGS cells reduces
cell migration and invasion activities
Our results confirmed high expression of GLO1 in advanced
gastric cancer, compared to noncancerous gastric mucosa. To
determine whether GLO1 expression is associated with invasive-
ness of gastric cancer cell lines, the effects of GLO1 depletion using
short hairpin (sh)RNA plasmids on tumor cell invasion activities of
TSGH or AGS cells were assessed. ShRNA expression vectors
encoding the antisense GLO1 sequence were transfected into
TSGH and AGS cell lines expressing high levels of endogenous
GLO1. GLO1 expression was significantly repressed in TSGH-
KG1, -KG2 (0.32- and 0.14-fold) and AGS-KS1, -KS2 (0.26- and
0.21-fold) sublines, respectively, compared with that in cells
transfected with the control vectors (C1, C2; Figs. 4A and B).
KG1 and KG2 GLO1-depleted cells exhibited significantly
(P,0.05) reduced migration rates (0.16- or 0.044-fold, respective-
ly) and invasion abilities (0.43- or 0.29-fold, respectively) than
control vector-transfected cells (Figs. 4C and D). Similar results
were obtained with AGS-KS cells (KS1 and KS2) (Figs. 4E and F).
Our results collectively suggest that GLO1 positively regulates the
migration and invasion abilities of gastric cancer cells.
Down-expression of GLO1 results in reduced expression
of genes involved in metastasis-associated pathways
To ascertain whether the GLO1 protein affects metastasis-
related genes, we compared the genome-wide expression of KG2
and C1. Several genes upregulated ($1.5-fold) in C1, compared to
KG2, were selected. MetaCore
TM analysis [28] revealed that the
top-ranking molecular pathways altered in KG clones were
Figure 3. Effects of GLO1 over-expression in SC-M1 cells. Two SC-M1-GLO1 over-expression clones (OG1 and OG2), and two control cell lines
(C1, C2) were established. (A) Expression of GLO1 was determined using western blot analysis. b-actin was used as an internal control. (B) Cell
proliferation, (C) Migration, and (D) Invasion abilities were assayed as described in ‘‘Materials and Methods’’. Data were presented as folds from at
least three independent experiments performed in duplicated. The fold changes (B–D), and differences examined using Mann-Whitney U method to
compare values with vector control. ** P,0.05.
doi:10.1371/journal.pone.0034352.g003
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metalloproteinase (MMP), CXCL8, and CXCL1] involved in those
pathways were down-regulated upon GLO1 silencing. Among the
cytokine related pathways, high expression of VEGF, CXCL8,
CXCR2, and CXCL1 are associated with cancer metastasis and
progression[8,29]. Previously, Daniel J.etal. [30] reportedthat over-
expression of GLO1 could enhance stromal cell-derived factor-1
(SDF-1), CXCR4, and VEGF expression in hypoxic endothelial
progenitor cells culture in high glucose. Therefore, we also analyzed
the expression of VEGF in KG stable lines.
We further validated the expression patterns of proteins in
VEGF or cytokine-related pathways via western blot analysis. The
levels of target genes, including CXCL1, CXCL8, CXCR2, and
VEGF, were significantly inhibited in TSGH-KG stable cell lines
(KG1 and KG2), compared with vector-transfected controls
(Fig. 5A). Furthermore, the levels of NF-kB and HIF1-a, well-
known transcription factors of pro-angiogenic growth factors (such
as CXCL8, CXCL1, and VEGF) [31], were reduced in the nuclei
of TSGH-KG stable cell lines, compared with control cells
(Fig. 5A). MMP2 and MMP9, the key enzymes for degrading type
IV collagen, are believed to play a critical role in tumor invasion
and metastasis [32]. Notably, depletion of GLO1 led to marked
suppression of MMP2 and MMP9 activities (Fig. 5B). Our data
indicate that GLO1 regulates the activation of metastasis-
associated signaling pathways in gastric cancer cells. Based on
these findings, we propose that GLO1 mediates gastric cancer cell
migration and invasion at least partially mediated through
activation of CXCL1, CXCL8, and VEGF.
IHC shows coexpression of GLO1 with CXCL1 and CXCR2
proteins and its over-expression in gastric cancerous
tissues
Earlier studies have reported that cytokine receptor interaction
and VEGF signaling pathways are associated with malignancy
features in gastric cancer [8,33]. Previously, our group showed a
significant association of CXCR2 and CXCL1 over-expression
(n=116) with gastric cancer progression [8]. Consistently, in IHC
analysis, a positive significant correlation was found exclusively
between the scores of GLO1 and CXCL1 or CXCR2 in cancer
tissues (Spearman’s correlation coefficient=0.238 and 0.293;
P=0.013 and P=0.003, respectively). Furthermore, immuno-
staining of consecutive sections revealed significant expression of
GLO1, CXCL1, and CXCR2 proteins in tumor epithelial cells
[Fig. 5C (b), (d), and (f)], in contrast to no or low expression in
noncancerous tissues [Fig. 5C (a), (c), and (e)].
Figure 4. Knockdown of GLO1 expression suppresses TSGH or
AGS cell migration and invasion. Two TSGH-GLO1-silenced clones
(KG1 and KG2), two AGS-GLO1-silenced clones (KS1 and KS2) sublines
and control cell lines (TSGH-C1 and -C2; AGS-C1 and -C2) were
established. (A, B) Expression of GLO1 was determined using western
blot analysis. b-actin was used as an internal control. Cell migration (C,
E) and invasion (D, F) abilities were assayed as described in ‘‘Materials
and Methods’’. Data were presented as folds from at least three
independent experiments performed in duplicated. The fold changes
(C–F), and differences examined using Mann-Whitney U method to
compare values with vector control. ** P,0.05.
doi:10.1371/journal.pone.0034352.g004
Figure 5. Downstream target genes of GLO1 and their clinical
correlations. (A) HIF-1a, NF-kB, VEGF, CXCL8, CXCL1, and CXCR2
protein levels in TSGH cells transfected with GLO1 shRNA (KG1 and KG2)
and control shRNA (C1 and C2). The gel was stained with Coomassie
blue (CB), which was used as a loading control of conditional media. b-
actin was used as an internal control for total cell lysates, and lamin A/C
for nuclear proteins. (B) Knockdown of GLO1 suppressed activation of
MMP2 and MMP9. Conditional media from C1, C2, KG1 and KG2 cells
were collected and subjected to gelatin zymography. (C) Sections of
formalin-fixed and paraffin-embedded tissues from three human gastric
tumor tissues were immunostained with anti-GLO1 (a and b), anti-
CXCL1 (c and d) or anti-CXCR2 antibodies (e and f). Coexpression of
GLO1, CXCL1, and CXCR2 proteins detected in human gastric cancer
tissues (b, d, and f). Noncancerous gastric mucosa with negative or
lower expression of GLO1, CXCL1 and CXCR2 proteins (a, c, and e). Scale
bar represents 200 mm.
doi:10.1371/journal.pone.0034352.g005
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Asthe secondmostfrequent causeofcancer-relateddeath,gastric
cancer remains a challenging disease. Data from the present study
demonstrated that upregulation of GLO1 in gastric cancer tissues is
significantly associated with tumor progression and advanced stages
of the disease. Concordantly, patients with lower GLO1 levels had
better disease prognosis. Moreover, qRT–PCR and IHC experi-
ments disclosed a correlation of increased GLO1 expression with
local tumor progression and lymph node invasion. We observed a
marked decrease in the metastasis and invasion abilities of GLO1-
deficientcells,concomitant with reduced levelsofseveral metastasis-
associated factors, including VEGF, CXCL1, CXCL8, MMPs, and
CXCR2. In the IHC study, a positive significant correlation
between GLO1 and CXCL1 expression patterns was observed in
resected specimens of gastric cancer. Moreover, elevated GLO1
and concomitant CXCL1 over-expression in patients with gastric
cancer were significantly correlated with survival. Our results
provide direct evidence supporting the involvement of GLO1 in
gastric cancer progression and the might through alternation of its
downstream migration and invasion pathways.
High expression of GLO1 has been linked to several cancers
[16,17]. Recent studies have suggested a vital role of GLO1 in
several cancer types in the removal of methylglyoxal (MG), which
is considered carcinostatic, resulting in the development of GLO1
inhibitors as anti-tumor agents [34,35]. Thus, high expression of
GLO1 is involved in cancer cell resistance to apoptosis induced by
anti-tumor agents [36]. Sakamoto et al. [36] proposed that GLO1
is not only a tumor but also a drug resistance marker. Consistently,
the GLO1 knockdown-clones were sensitive to several chemo-
therapy agents such as camptothecin, etoposide (data not shown).
Clinically, our results indicate that GLO1 is highly expressed in
gastric cancer and significantly associated with tumor progression
and advanced stages of the disease.
Glycolytic alterations in cancer cells represent a metabolic
adaptation to hypoxic tumors via the action of hypoxia-induced
transcription factor (HIF-1) [37,38]. In addition, the transcription
factors, HIF1-a and NF-kB, play crucial roles in various processes,
suchas inflammation, microbial killingand cancer progression [39].
Tumor hypoxia appears to be strongly associated with tumor
propagation, malignant progression, and resistance to therapy. The
HIF-1a pathway is clearly involved in carcinogenesis of gastric
cancer [39]. In addition, immunohistochemical expression of HIF-
1a target genes (Glut1, VEGF, CA9, iNOS) is associated with
gastric tumor progression [40]. Among the oncogenic pathways,
NF-kB signaling is elevated in a significant proportion of gastric
cancers [9]. Moreover, several lines of evidence support crosstalk
between the NF-kB and HIF-1a signaling pathways [41]. In our
experiments, levels of both HIF-1a and NF-kB were reduced in
nuclei upon GLO1 silencing in gastric cancer cell lines, along with
downstream target genes (VEGF, CXCL1, CXCL8, MMPs).
In our study, abnormally elevated GLO1 expression was
associated with progressive phenotypes, such as gastric wall
invasion, lymph node metastasis, pathological stage, and lymphat-
ic invasion. Previously, we reported that elevated CXCL1 and
CXCR2 in gastric cancer is associated with tumor progression,
and that the plasma CXCL1 level may be a useful circulating
biomarker for gastric cancer diagnosis [8]. Here, we have obtained
direct clinical evidence of a strong correlation between the
expression patterns of GLO1 and CXCL1 or CXCR2. GLO1
expression may be associated with activation of cytokine receptor
associated and VEGF signaling pathways, representing a potential
mechanism for enhanced motility and invasive ability. Our results
confirm over-expression of GLO1 in gastric carcinoma and its
strong association with advanced stages and poor prognosis.
Earlier studies by our group have shown that SPARC [18], CLIC1
[42], SLPI [43], CXCL1, CXCL8, and CXCR2 are highly
expressed and associated with advanced stages and poor prognosis
of gastric cancer [8]. These novel potential biomarkers may
therefore be applied to improve the specificity and sensitivity of
gastric cancer diagnosis. Further development and confirmation of
the utility of these markers in larger patient cohorts will potentially
lead to clinical applications.
Supporting Information
Figure S1 The specificity of in-house GLO1 was validated by
western blot analysis. Rabbit polyclonal anti-GLO1 antibody
(right image) and negative control pre-immune sera (left image)
were used. The GLO1 protein level was determined in TSGH-C1
and -KG2 gastric cell lines with the in-house GLO1 antibody. b-
actin was used as an internal control for total cell lysates.
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